Developing new antibiotic treatments, promoting responsible use, and ensuring access for all


The Global Antibiotic Research & Development Partnership (GARDP) was established in May 2016 as a joint initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi). The mission of this not-for-profit research and development (R&D) initiative is to develop new antibiotic treatments addressing antimicrobial resistance and to promote their responsible use for optimal conservation, while ensuring equitable access for all in need. In 2018, GARDP set up as an independent legal entity.


How does GARDP work?

A partnership model for product development, based on the experience gained from the field of neglected diseases, can provide an important element of the overall strategy for R&D in the field of antibiotics. Such a partnership can test new incentives that also contribute to conservation of and access to new antibiotic treatments. By doing so, it can provide an important alternative to the traditional market-driven pharmaceutical approach, by focusing on products that the pharmaceutical industry will likely not develop for lack of profitability.

GARDP works closely with all stakeholders in the field of antibiotic R&D – including pharmaceutical and biotechnology companies, startups, other product development partnerships, academia, civil society, and health authorities – from countries of all income levels – to develop new antibiotic treatments.




  • addresses global public health and specific needs of low- and middle-income countries;
  • targets products that industry will likely not develop due to lack of profitability or other reasons;
  • pilots the use of alternative incentive models delinking cost of R&D from volume-based sales and prices of antibiotics, which support conservation of and access to new antibiotics; and
  • ensures that new antibiotics developed by GARDP are affordable to all in need.


Read GARDP’s 
2017 Activity Report

R&D Strategy

To ensure that GARDP focuses its scientific portfolio towards meeting priority needs, its R&D prioritization process begins with the requirement that any programme meets at least two out of three key criteria:

1. Target priority pathogens

2. Address priority diseases and syndromes

3. Help under-served priority patient populations

Read the GARDP R&D Strategy


GARDP’s objectives: 2017-2023

  • Develop and deliver up to four new treatments through improvement of existing antibiotics and acceleration of the entry of new chemical entities. Build a robust pipeline of pre-clinical and clinical candidates with up to four candidates brought into pre-clinical or clinical development.
  • Secure EUR 270 million to execute its R&D programmes, build a highly experienced R&D team, and establish a dedicated entity.
  • Support and advocate for appropriate use of antibiotics, sustainable access, and suitable financing of R&D for new antibiotic treatments.